What side effects are most important to watch for with Rybelsus
GLP-1 medications are approved for adults who have a body mass index (BMI) of 30 or higher, or a BMI of at least 27 plus a weight-related medical condition, such as the following: Type 2 diabetes High blood pressure High cholesterol Obstructive sleep apnea Cardiovascular disease that increases the risk of heart attack or stroke MASH, or metabolic dysfunctionassociated steatohepatitis, a form of liver inflammation Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine, notes that qualifying for the medication based on heart disease aloneoften necessary for insurance coveragecan be challenging
Pricing changed substantially in late 2025 and 2026
It hasnt been thoroughly tested for safety or efficacy, which means this weight loss drug could put your health at risk
Q: How much weight loss did retatrutide show in clinical trials
Some patients may have compensatory mechanisms that maintain hunger signals despite GLP-1 receptor activation
